Literature DB >> 14577496

The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.

Erim Erdem1, Necmettin Atsü, Cem Akbal, Cenk Y Bilen, Ali Ergen, Haluk Ozen.   

Abstract

OBJECTIVES: Curative therapy and extended period of disease free survival for patients with prostate cancer is possible only if the radical prostatectomy is performed when the disease is organ confined. It has been shown that combined use of local clinical stage, Gleason score of transrectal needle biopsy and serum PSA can accurately predict the final pathological stage in men undergoing radical prostatectomy. Recently the free/total PSA (F/T PSA) has been shown to improve the specificity of serum PSA level in early detection prostate cancer. In this study the utility of F/T PSA ratio in prediction the final pathological features of the prostate cancer was investigated.
METHODS: 52 patients who had undergone radical prostatectomy were included in this study with mean age of 63 (ranging from 49 to 73). According to the pathologic features of the tumors, patients were classified as organ confined in 37 (%71), specimen-confined in 39 (%75) and as with favorable pathology which was defined as organ confined or specimen confined with Gleason score lower than 7, 39 (%75) patients.
RESULTS: Neither total PSA levels nor F/T PSA values correlate significantly with the pathological characteristics of the tumor. The logistic regression analysis showed that the biopsy Gleason score was the only variable that was able to predict the pathology of the tumor (p < 0,05).
CONCLUSION: As a conclusion Gleason score of the needle biopsy specimen is the most predictive factor of the final pathological outcome. F/T PSA ratio did not provide additional information about predicting pathological stage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 14577496     DOI: 10.1023/a:1025685718493

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  13 in total

1.  Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.

Authors:  P C Southwick; W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; P C Walsh; P T Scardino; P H Lange; G H Gasior; R E Parson; K G Loveland
Journal:  J Urol       Date:  1999-10       Impact factor: 7.450

2.  The free-to-total serum prostatic specific antigen ratio as a predictor of the pathological features of prostate cancer.

Authors:  J Morote; G Encabo; M A Lopez; I M De Torres
Journal:  BJU Int       Date:  1999-06       Impact factor: 5.588

Review 3.  The use of percent free prostate specific antigen for staging clinically localized prostate cancer.

Authors:  J Pannek; H G Rittenhouse; D W Chan; J I Epstein; P C Walsh; A W Partin
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

4.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Authors:  A W Partin; J Yoo; H B Carter; J D Pearson; D W Chan; J I Epstein; P C Walsh
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

5.  Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy.

Authors:  D A Ackerman; J M Barry; R A Wicklund; N Olson; B A Lowe
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

6.  Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.

Authors:  J E Oesterling; C B Brendler; J I Epstein; A W Kimball; P C Walsh
Journal:  J Urol       Date:  1987-07       Impact factor: 7.450

7.  Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.

Authors:  M E Sands; G K Zagars; A Pollack; A C von Eschenbach
Journal:  Urology       Date:  1994-08       Impact factor: 2.649

8.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Prediction of capsular perforation and seminal vesicle invasion in prostate cancer.

Authors:  D G Bostwick; J Qian; E Bergstralh; P Dundore; J Dugan; R P Myers; J E Oesterling
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

10.  Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.

Authors:  P Narayan; G Fournier; V Gajendran; R Leidich; R Lo; J S Wolf; G Jacob; G Nicolaisen; K Palmer; F Freiha
Journal:  Urology       Date:  1994-10       Impact factor: 2.649

View more
  3 in total

1.  Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy?

Authors:  Cavit Ceylan; Eymen Gazel; İbrahim Keleş; Ömer Doluoğlu; Metin Yığman
Journal:  Curr Urol       Date:  2016-02-10

2.  Overdiagnosis of prostate cancer.

Authors:  Gurdarshan S Sandhu; Gerald L Andriole
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

3.  Predictive model using prostate MRI findings can predict candidates for nerve sparing radical prostatectomy among low-intermediate risk prostate cancer patients.

Authors:  Gang Song; Mingjian Ruan; He Wang; Zhiyong Lin; Xiaoying Wang; Xueying Li; Peng Li; Yandong Wang; Binyi Zhou; Xuege Hu; Hua Liu; Hao Wang; Yinglu Guo
Journal:  Transl Androl Urol       Date:  2020-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.